SG11201803813UA - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents
1,3,4-thiadiazole compounds and their use in treating cancerInfo
- Publication number
- SG11201803813UA SG11201803813UA SG11201803813UA SG11201803813UA SG11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA
- Authority
- SG
- Singapore
- Prior art keywords
- cambridge
- international
- astrazeneca
- building
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260787P | 2015-11-30 | 2015-11-30 | |
| PCT/EP2016/079251 WO2017093300A1 (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803813UA true SG11201803813UA (en) | 2018-06-28 |
Family
ID=57421876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803813UA SG11201803813UA (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9938265B2 (ko) |
| EP (1) | EP3383871B1 (ko) |
| JP (1) | JP6873132B2 (ko) |
| KR (1) | KR20180083412A (ko) |
| CN (1) | CN108349967B (ko) |
| AR (1) | AR106876A1 (ko) |
| AU (1) | AU2016363719B2 (ko) |
| BR (1) | BR112018010812A2 (ko) |
| CA (1) | CA3005516C (ko) |
| CL (1) | CL2018001408A1 (ko) |
| CO (1) | CO2018006929A2 (ko) |
| DK (1) | DK3383871T3 (ko) |
| DO (1) | DOP2018000134A (ko) |
| EA (1) | EA201891240A1 (ko) |
| ES (1) | ES2759940T3 (ko) |
| IL (1) | IL258644A (ko) |
| MX (1) | MX2018006528A (ko) |
| NI (1) | NI201800065A (ko) |
| PE (1) | PE20181450A1 (ko) |
| PH (1) | PH12018501132A1 (ko) |
| SG (1) | SG11201803813UA (ko) |
| SV (1) | SV2018005701A (ko) |
| TN (1) | TN2018000126A1 (ko) |
| TW (1) | TW201730188A (ko) |
| WO (1) | WO2017093300A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201733587A (zh) * | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| JP7026852B2 (ja) * | 2018-10-16 | 2022-02-28 | メッドシャイン ディスカバリー インコーポレイテッド | チアジアゾール誘導体及びｇｌｓ１阻害剤としてのその使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003514910A (ja) * | 1999-11-24 | 2003-04-22 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類 |
| US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| AR044688A1 (es) * | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
| US8003806B2 (en) * | 2004-11-12 | 2011-08-23 | OSI Pharmaceuticals, LLC | Integrin antagonists useful as anticancer agents |
| EP2421826B1 (en) * | 2009-04-20 | 2013-10-23 | F.Hoffmann-La Roche Ag | Proline derivatives as cathepsin inhibitors |
| CA2856386C (en) | 2011-11-21 | 2022-05-31 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| EP3954686A1 (en) * | 2012-11-16 | 2022-02-16 | Calithera Biosciences, Inc. | Heterocyclic glutaminase inhibitors |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| KR20220013017A (ko) * | 2014-01-06 | 2022-02-04 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| EP3116872A4 (en) * | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201731511A (zh) | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | １，３，４-噻二唑化合物及其在治療癌症中之用途 |
-
2016
- 2016-11-29 TW TW105139312A patent/TW201730188A/zh unknown
- 2016-11-29 US US15/363,018 patent/US9938265B2/en active Active
- 2016-11-30 JP JP2018526717A patent/JP6873132B2/ja active Active
- 2016-11-30 EP EP16802102.0A patent/EP3383871B1/en active Active
- 2016-11-30 ES ES16802102T patent/ES2759940T3/es active Active
- 2016-11-30 KR KR1020187017164A patent/KR20180083412A/ko unknown
- 2016-11-30 AU AU2016363719A patent/AU2016363719B2/en active Active
- 2016-11-30 AR ARP160103665A patent/AR106876A1/es unknown
- 2016-11-30 TN TNP/2018/000126A patent/TN2018000126A1/en unknown
- 2016-11-30 BR BR112018010812A patent/BR112018010812A2/pt not_active Application Discontinuation
- 2016-11-30 CN CN201680067261.2A patent/CN108349967B/zh active Active
- 2016-11-30 PE PE2018001021A patent/PE20181450A1/es unknown
- 2016-11-30 SG SG11201803813UA patent/SG11201803813UA/en unknown
- 2016-11-30 EA EA201891240A patent/EA201891240A1/ru unknown
- 2016-11-30 DK DK16802102.0T patent/DK3383871T3/da active
- 2016-11-30 WO PCT/EP2016/079251 patent/WO2017093300A1/en active Application Filing
- 2016-11-30 CA CA3005516A patent/CA3005516C/en active Active
- 2016-11-30 MX MX2018006528A patent/MX2018006528A/es unknown
-
2018
- 2018-04-11 IL IL258644A patent/IL258644A/en unknown
- 2018-05-24 CL CL2018001408A patent/CL2018001408A1/es unknown
- 2018-05-29 PH PH12018501132A patent/PH12018501132A1/en unknown
- 2018-05-29 DO DO2018000134A patent/DOP2018000134A/es unknown
- 2018-05-29 SV SV2018005701A patent/SV2018005701A/es unknown
- 2018-05-29 NI NI201800065A patent/NI201800065A/es unknown
- 2018-06-29 CO CONC2018/0006929A patent/CO2018006929A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018001408A1 (es) | 2018-10-12 |
| TW201730188A (zh) | 2017-09-01 |
| US20170152254A1 (en) | 2017-06-01 |
| PH12018501132A1 (en) | 2019-01-21 |
| EA201891240A1 (ru) | 2018-11-30 |
| CA3005516C (en) | 2024-04-16 |
| IL258644A (en) | 2018-06-28 |
| DK3383871T3 (da) | 2019-12-16 |
| SV2018005701A (es) | 2018-11-27 |
| CO2018006929A2 (es) | 2018-10-10 |
| EP3383871A1 (en) | 2018-10-10 |
| EP3383871B1 (en) | 2019-09-11 |
| DOP2018000134A (es) | 2018-06-30 |
| CN108349967B (zh) | 2022-02-15 |
| US9938265B2 (en) | 2018-04-10 |
| WO2017093300A1 (en) | 2017-06-08 |
| AR106876A1 (es) | 2018-02-28 |
| JP6873132B2 (ja) | 2021-05-19 |
| AU2016363719B2 (en) | 2019-11-14 |
| PE20181450A1 (es) | 2018-09-12 |
| AU2016363719A1 (en) | 2018-07-05 |
| CN108349967A (zh) | 2018-07-31 |
| AU2016363719A8 (en) | 2018-07-12 |
| NI201800065A (es) | 2018-10-18 |
| BR112018010812A2 (pt) | 2018-11-27 |
| ES2759940T3 (es) | 2020-05-12 |
| CA3005516A1 (en) | 2017-06-08 |
| JP2019501134A (ja) | 2019-01-17 |
| TN2018000126A1 (en) | 2019-10-04 |
| KR20180083412A (ko) | 2018-07-20 |
| MX2018006528A (es) | 2019-05-15 |
| ES2759940T8 (es) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors |